NeuroVive's KL1333 Program Granted Orphan Drug Designation by the European Commission

LUND, Sweden, Dec. 13, 2017 /PRNewswire/ --NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF), announced today that the European Commission has granted orphan drug designation (ODD) for the company's KL1333 program for oral treatment of the genetic mitochondrial disease...